Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BI 703704, a soluble guanylate cyclase (sGC) activator, inhibits the progression of diabetic nephropathy in the ZSF1 rat [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 1,520.00 | |
50 mg | 10-14 weeks | $ 1,980.00 | |
100 mg | 10-14 weeks | $ 2,500.00 |
Description | BI 703704, a soluble guanylate cyclase (sGC) activator, inhibits the progression of diabetic nephropathy in the ZSF1 rat [1]. |
In vivo | BI 703704 administered at dosages of 0.3 to 10 mg/kg through food intake daily for 15 weeks in fifty-eight male ZSF1 rats aged 12-13 weeks led to a dose-dependent reduction in urinary protein excretion (UPE) and a dose-dependent elevation in renal cGMP levels [1]. The compound effectively increases renal cGMP in a dose-responsive manner, thereby decelerating the progression of diabetic nephropathy under conditions of oxidative stress [1]. |
Molecular Weight | 559.72 |
Formula | C32H37N3O4S |
CAS No. | 2740807-77-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BI 703704 2740807-77-4 Others BI-703704 BI703704 inhibitor inhibit